RecruitingPhase 2NCT06349980

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Henlius Biotech
Principal Investigator
Jia Fan
Fudan University
Intervention
HLX53 (1000mg)(drug)
Enrollment
117 target
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06349980 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials